ChemPartner, a leading global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announced its strategic U.S. expansion with the opening of the ChemPartner Boston Center of Excellence. The new R&D facility, located at 480 Arsenal Way in Watertown, Massachusetts, will commence operations on September 10, 2025, providing discovery and preclinical services to biopharma clients in North America and beyond.
Strategic Positioning in Boston Biotech Hub
The 12,000 square foot facility is strategically positioned in the heart of the Boston biotech corridor to strengthen collaboration with the region's innovative biotech and pharmaceutical community. "As demand grows for more localized, agile, and collaborative research partnerships, this expansion reflects our commitment to meeting clients where they are - both scientifically and geographically," said William Woo, Chairman and CEO of ChemPartner.
The Boston Center of Excellence will offer biologics discovery, pharmacology, and DMPK services, supporting both in vitro and in vivo studies from early discovery through IND-enabling stages. As an extension of ChemPartner's global network, the facility enhances flexibility for North American partners needing onshore capabilities while improving logistics and enabling faster, more seamless coordination across regions.
Addressing Industry Challenges
The expansion directly responds to increasing complexity in the biopharma sector. "Our partners face increasing complexity, from bespoke service needs and tighter timelines to evolving regulatory requirements and shipping restrictions," said Yinfei Yin, Managing Director of ChemPartner US. "The Boston Center of Excellence will address these challenges head-on while upholding the scientific expertise ChemPartner is known for."
The facility will open with an experienced scientific team ready to support clients locally and globally. Equipment installation is currently underway, with initial projects slated to launch this fall.
Global Network Integration
ChemPartner US Corporation operates as the wholly owned subsidiary of ChemPartner Group, offering a comprehensive range of drug discovery, development, and manufacturing services including chemistry and biologics discovery, pharmacology, DMPK, and exploratory toxicology and development and manufacturing CDMO services. Shanghai ChemPartner serves a diverse global client base, with laboratories, business offices, and representatives in the U.S., Europe, China, and Australia.
The Boston expansion represents ChemPartner's commitment to delivering more personalized, streamlined support across the drug discovery and development pipeline while embedding the company within one of the world's most prominent life sciences ecosystems.
